Khuri FR - Search Results

1

Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?

O'Regan RM, Khuri FR. O'Regan RM, et al. Among authors: khuri fr. Endocr Relat Cancer. 2004 Jun;11(2):191-205. doi: 10.1677/erc.0.0110191. Endocr Relat Cancer. 2004. PMID: 15163298 Review.

2

Chemoprevention in lung cancer.

Reddy SC, Khuri FR. Reddy SC, et al. Among authors: khuri fr. J Med Assoc Ga. 2003 Winter-Spring;92(1):27-33. J Med Assoc Ga. 2003. PMID: 12743903 Review. No abstract available.

3

Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.

Chun KH, Lee HY, Hassan K, Khuri F, Hong WK, Lotan R. Chun KH, et al. Cancer Res. 2003 Aug 15;63(16):4796-800. Cancer Res. 2003. PMID: 12941797

4

Emerging drugs for head and neck cancer.

Rhee JC, Khuri FR, Shin DM. Rhee JC, et al. Among authors: khuri fr. Expert Opin Emerg Drugs. 2004 May;9(1):91-104. doi: 10.1517/eoed.9.1.91.32953. Expert Opin Emerg Drugs. 2004. PMID: 15155138 Review.

5

Novel targeted agents in the treatment of lung cancer.

Saba N, Khuri F. Saba N, et al. Expert Opin Investig Drugs. 2004 Jun;13(6):609-29. doi: 10.1517/13543784.13.6.609. Expert Opin Investig Drugs. 2004. PMID: 15174948 Review.

6

Molecularly targeted approaches to the chemoprevention of lung cancer.

Khuri FR, Cohen V. Khuri FR, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4249s-4253s. doi: 10.1158/1078-0432.CCR-040019. Clin Cancer Res. 2004. PMID: 15217968 Review.

7

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.

Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, DeVore RF 3rd, De Porre PM, Richards HM, Jia X, Zhang S, Johnson BE. Heymach JV, et al. Among authors: khuri fr. Ann Oncol. 2004 Aug;15(8):1187-93. doi: 10.1093/annonc/mdh315. Ann Oncol. 2004. PMID: 15277257 Free article. Clinical Trial.

8

The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.

Sun SY, Zhou Z, Wang R, Fu H, Khuri FR. Sun SY, et al. Among authors: khuri fr. Cancer Biol Ther. 2004 Nov;3(11):1092-8; discussion 1099-1101. doi: 10.4161/cbt.3.11.1176. Epub 2004 Nov 12. Cancer Biol Ther. 2004. PMID: 15467440 Free article.

9

The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.

Marcus AI, Zhou J, O'Brate A, Hamel E, Wong J, Nivens M, El-Naggar A, Yao TP, Khuri FR, Giannakakou P. Marcus AI, et al. Among authors: khuri fr. Cancer Res. 2005 May 1;65(9):3883-93. doi: 10.1158/0008-5472.CAN-04-3757. Cancer Res. 2005. PMID: 15867388 Free PMC article.

10

Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells.

Ren H, Tai SK, Khuri F, Chu Z, Mao L. Ren H, et al. Cancer Res. 2005 Jul 1;65(13):5841-7. doi: 10.1158/0008-5472.CAN-04-3141. Cancer Res. 2005. PMID: 15994961

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

486 results

Search Page

Filters